Sklamberg Discusses Cannabis Rescheduling On NPR's 1A Podcast

AP
Arnold & Porter

Contributor

Arnold & Porter is a firm of more than 1,000 lawyers, providing sophisticated litigation and transactional capabilities, renowned regulatory experience and market-leading multidisciplinary practices in the life sciences and financial services industries. Our global reach, experience and deep knowledge allow us to work across geographic, cultural, technological and ideological borders.
Howard Sklamberg, Life Sciences & Healthcare Regulatory partner and former FDA Deputy Commissioner, was recently a guest on NPR's podcast 1A for its episode...
United States Cannabis & Hemp
To print this article, all you need is to be registered or login on Mondaq.com.

Howard Sklamberg, Life Sciences & Healthcare Regulatory partner and former FDA Deputy Commissioner, was recently a guest on NPR's podcast 1A for its episode, "For the first time, the government is acknowledging marijuana's potential medical benefits." The episode discussed the recent move by Attorney General Merrick Garland to initiate the process of reclassifying cannabis as a Schedule III drug and what this change would mean for drug policy and cannabis research.

Listen to the full episode.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More